The young company Alveolix received one of the coveted Innosuisse 2019 certificates. Alveolix is a spin-off from the University of Berne and offers in vitro solutions based on proprietary and unique organ-on-chip technologies that aim to improve preclinical decision-making and thus reduce drug development costs. The certificate is an important milestone and certifies that Alveolix is now ready for sustainable growth.
We congratulate the Alveolix team on this success. We were pleased to accompany Alveolix as Innosuisse Coach.